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Abstract 
 
Ubiquitin C-terminal hydrolase-1 (UCH-L1), an endoprotease that cleaves the 
specific peptide bond between the ubiquitin molecules, is released in the serum and 
cerebrospinal fluid (CSF) following severe brain injury. The level of UCHL1 in 
serum and CSF is inversely proportional to the chance of survival and therefore an 
important biomarker for brain injury. We developed a sensitive and accurate 
colorimetric assay using gold nanoparticles (30nm) based on surface plasmon 
resonance-dependent absorption of visible light at 520nm. Synthesising a specific 
ubiquitin polypeptide substrate for UCHL1 with two terminal thiol groups, we 
allowed gold nanoparticles to interact. This resulted blue colour aggregation of 
substrate polypeptide and nanoparticles with an absorption maxima of 600nm. On 
addition of UCHL1 to these aggregate, substrate polypeptide molecules was cleaved 
at the specific position and clustered gold nanoparticles became dispersed resulting 
the absorption maxima shifting to 520nm and changing the blue colour to red. 
Presently severity of brain injury is diagnosed using neuro-imaging such as CT 
scanning and MRI. Simple and inexpensive biochemical assay that we developed 
might help the physicians to quickly determine severity of the damage, monitor the 
progress of the treatment and ultimately predict the risk of death of individual 
patients.  
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 Chapter 1  
Introduction and Objectives 
 
1.Introduction: 
Ubiquitination and deubiquitination: Ubiquitin is a 76-amino acid polypeptide 
found in all eukaryotes. The covalent attachment of ubiquitin to the cellular proteins 
targets them for proteasomal degradation. Ubiquitin-mediated protein modification 
also plays a crucial role in various cellular processes, including stress response, 
signal transduction and cell differentiation. By contrast, the deubiquitination 
reverses the ubiquitination process and is carried out by deubiquitinating enzymes 
(DUBs). DUBs play two key roles in the ubiquitin pathway. First, ubiquitin is 
always expressed either as a pro-protein fused to one of two ribosomal proteins or as 
linear polyubiquitin, consisting of multiple copies of monoubiquitin that must be 
processed to yield the mature ubiquitin monomer. Second, DUBs reverse the 
ubiquitination or ubiquitin-like modification of target proteins. Thus far, about 100 
human DUBs have been identified, and based on the sequence similarity, they have 
been classified into ubiquitin C-terminal hydrolases (UCHs) and Ub-specific 
proteases (UBPs). Both classes are thiol proteases that hydrolyze the isopeptide 
bond between the substrate and the C-terminal Glycine 76 of ubiqitin.  
The UCH family of DUBs is generally small in size (~20-30kDa), and they cleave 
ubiquitin from relatively small protein substrates of up to 20-30 amino acids. The 
sequences are well conserved across species with approximately 40% identities and 
they are structurally similar to the papain cysteine proteases. Like papain family of 
cysteine proteases, the active site catalytic triad of UCH family of DUBs consists of 
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Cysteine, Histidine and Aspartate. Structural analysis also revealed a 20 aminoacid 
residues loop near the active site (called ‘active-site crossover loop’) which plays an 
important role in substrate binding and a induces a conformational rearrangement of 
the active site in order for hydrolytic activity. Among the human UCHs, UCHL1 is 
one of the most abundant proteins in the brain and immuno-histological experiments 
demonstrate that it is localized exclusively to neurons [37]. UCHL1 associates with 
ubiquitin in neuronal cells and this association is important for the maintenance of 
mono-ubiquitin levels in neurons. UCHL1 effectively up-regulates ubiquitin levels 
at the post-translational level, and this upregulation is probably based on the 
inhibition of ubiquitin degradation by UCHL1 [28]. 
1.2. Brain damage biomarker: Severe head injury that damages internal brain 
tissue is one of the leading causes of death and disability. Unlike other organ-based 
injuries or diseases where rapid diagnosis is available, no diagnostic tests have been 
developed for serious brain injury. Currently, diagnosis depends on a variety of 
measures including neurological examination and neuroimaging such as CT 
scanning and MRI, all of which have some limitations. CT scanning has low 
sensitivity to diffuse brain damage and the MRI is not widely available and rather 
expensive. A blood biomarker-based simple and inexpensive diagnosis will help the 
physician to quickly determine severity of the damage, monitor the progress of the 
treatment and ultimately predict the chance of survival of patients. Previous studies 
established few protein biomarkers for brain injury [3, 9]. These include neuron-
specific enolase (NSE), glial protein S-100β, myelin basic protein (MBP) and a 
deubiquitinase, known as ubiquitin carboxy-terminal hydrolase-1 (UCHL1) [10, 26, 
31, 39]. Although NSE, S100β, and MBP was shown to be released in the blood 
following brain damage, conflicting results made their utility uncertain [20, 25]. On 
3 
the contrary, UCHL1 protein is a present exclusively in the neuron (unlike NSE and 
S100B, which are also present in non-neural tissues) [10]. UCHL1 (historically 
known as PGP 9.5) was first detected as a 'brain-specific protein' over 30 years ago 
[15]. It has been shown that UCHL1 is released in the cerebrospinal fluid (CSF) 
after ischemic and traumatic brain injury in rats [23]. Clinical study with several 
brain injury patients established that higher level of UCHL1 in serum and CSF is 
inversely proportional to chance of survival [4, 27, 30]. Since there are no other 
endopeptidases known to be present in the serum and CSF, a robust assay to detect 
UCHL1 in brain injury patients would help in monitoring the progress of the 
treatment. 
1.3. UCH-L1 as Brain damage biomarker: The Ubiquitin C-terminal hydrolases 
(UCH) are a group of DUBs that are specifically hydrolyse the peptide bond 
following the C-terminal Gly of Ubiquitin. To date, four UCH enzymes have been 
identified from human cells: UCH-L1, UCH-L3, UCH-L5 and BAP1 (BRCA1-
associated protein 1). Among these, UCH-L1 is a highly specific neuronal protein 
that is concentrated in the grey matter region of the brain [5]. This 24kDa enzyme 
constitutes 10% of neuronal cytosolic proteins[15]. Physiological role of UCH-L1 is 
to remove conjugated ubiquitin from degradation-targeted proteins which is 
important for protein turnover in neurons. Often, misfolded proteins, if not 
appropriately catabolized, could result in protein aggregation which is neurotoxic. 
Human studies have also linked UCH-L1 to degenerative CNS diseases such as 
Parkinson’s disease and Alzheimer’s disease [11]. UCH-L1 has also been shown to 
be biomarker of neuronal loss during brain haemorrhage [21]. Presence of UCH-L1 
in the CSF after serious brain injury has been discovered recently and clinical 
studies established the strong correlation between concentration of UCHL1 and 
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outcome of the treatment [4, 27, 30]. UCH-L1 is an excellent biomarker for several 
reasons: (1) UCH-L1 is highly expressed almost exclusively in the brain. (2) UCH-
L1 can cross brain-blood barrier as it is a small protein with a molecular weight of 
about 24 kDa and has a compact and almost globular shape [16]. (3) It is stable in 
the biofluid as western blots of CSF fluids revealed that it remains as an intact 
protein with no detectable breakdown product [4]. UCH-L1 level could increase 25-
50 fold following injury and detectable within 6 hrs of injury and peaks within the 
first 24 hrs [30]. Ubiquitination and deubiquitination play pivotal roles in many 
biological processes. Although UCHL1 could be an important biomarker, till date 
there is no simple method to detect UCH-L1 during brain injury. 
1.4. Gold nanoparticle-based biomarker detection. Optical properties of gold NPs 
can be used as a means to obtain information on processes occurring in the solution. 
It is well established that gold NPs of ~10-40nm diameter display an absorption at 
520nm due to the excitation of the surface plasmon which shifts to longer 
wavelengths (600nm) upon cluster formation. The progress of the aggregate 
formation can be followed with the naked eye as the colour of the solution changes 
from red to blue. The possibility to control nanoparticle aggregation has been 
exploited in many areas of chemical sensing and enzyme bioassays. For example, 
gold NPs have been used for assaying superoxide dismutase, phosphatase, 
Acetylcholine esterase, lactamase, protease, lysozyme, nuclease, thrombin and 
glucose oxidase [6-8, 13, 14, 18, 24, 29, 35, 36, 38]. However, gold NPs have not 
been used to assay any ubiquitinating or deubiquitinating enzyme. Thus, developing 
gold NP based UCH-L1 assay method for detection in clinical samples is the main 
aspect of the proposed project. 
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 In India, active research is being carried out on gold NPs based chemical 
sensing [29]. However, there has been no study anywhere in the World on utilizing 
deubiquitining enzymes for clinical application. This gives a broad room to apply 
the existing knowledge of gold NPs and biochemistry of UCH-L1 as biomarker for 
brain injury. Therefore, research initiative in this direction in India will be useful as 
a new area in translational research. 
1.5. Rationale of gold nanoparticle based biomarker detection. In this proposal 
we will exploit two unique properties of the gold nanoparticles (gold NPs): (1) It is 
well known that the gold NPs of 10-50 nm diameter exhibit localized surface 
plasmon resonance (SPR) that results in absorption at 520 nm displaying intense red 
colour. On aggregation of the gold NPs, the optical properties change and absorption 
maxima shift to longer wavelengths of 600nm turning the colour to blue. Such 
clearly distinguishable and predictable colour change during gold NP aggregation or 
re-dispersion provides would provide an elegant platform for developing the 
absorption-based colorimetric detection system that can be performed without any 
sophisticated instruments. Because of the extremely high extinction coefficients of 
gold NPs, this assay would provide sensitivity comparable to conventional analytical 
methods such as ELISA.  (2) It was shown that gold NPs also interact strongly with 
thiol-groups and peptide featuring a head and tail thiol-groups causes aggregation of 
gold NPs [12]. These two characteristics of the gold NPs can be utilized in an 
artificially designed polypeptide substrate containing two thiol-groups at the two 
termini for UCHL1 endoprotease detection.  
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2. Objective 
We hypothesize that presence of the UCHL1 substrate peptides will cause thiol-
mediated interaction and aggregation of gold NPs resulting in blue colour. On 
addition of sample containing UCHL1 these substrate peptide molecules will be 
cleaved at the specific position by endopeptidase activity of UCHL1 and gold NPs 
will become dispersed resulting the changing of colour to red. A pictorial overview 
of the proposed assay is depicted. The proposed project aims to develop a rapid and 
simple assay using gold nanoparticle for the detection of presence of UCHL1 in the 
clinical samples. In order to achieve this objective, the project will be focused on the 
following specific objectives: 
 
 
Objective 1: Gold nanoparticle-based assay for detection of UCH-L1 
Specific aim-1: Synthesis of a specially designed thiol-ubiquitin substrate specific 
to UCHL1: The polypeptide substrate used for detecting the UCHL1 activity will be 
modified to incorporate two terminal thiol groups which will be contributed by 
cysteine residues. Site-directed mutagenesis approach will be used to incorporate 
these two cysteine residues.  
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Specific aim-2: Aggregation of Gold NP by using the thiol-ubiquitin substrate: The 
appropriate concentration of thiol-containing peptide substrate required and optimal 
buffer composition that induces aggregation of gold NPs without causing 
precipitation by nonspecific aggregation will be determined empirically. The thiol-
ubiquitin substrate-induced aggregation of gold NPs process will be monitored by 
recording the change of absorbance as absorption maxima (530nm) of dispersed 
gold NP colloids is different from aggregated gold NPs (650nm).  
Specific aim-3: Cleavage of thiol-ubiquitin substrate by UCHL1 and induced 
dispersion of Gold NP: Thiol-ubiquitin substrate-induced gold NPs aggregate will be 
used as substrate for UCHL1 mediated cleavage. The decrease of absorbance at 
650nm and increase at 530nm and colour change from blue to red would be the 
indicator of UCHL1 mediated dispersion of Gold NPs.  
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                                   Chapter 2 
  
 Materials and Methods           
 
Buffers, Media and Solutions: 
Deionised water was used for all buffers solutions and media 
LB medium 
1 % w/v Tryptone (HIMEDIA,#G010) 
0.5 % w/v yeast extract (HIMEDIA,# RM027) 
SOC medium 
2 % w/v Tryptone (HIMEDIA,#G010) 
0.5 % w/v yeast extract (HIMEDIA,# RM027) 
TB medium 
1% w/v yeast extract(HIMEDIA,# RM027) 
 0.5% w/v tryptone(HIMEDIA,#G010) 
TE (Tris-EDTA) [50X] 
1 mM Tris-HCl pH 8.0 
0.1 mM EDTA pH 8.0 
A 10 x stock solution was routinely used to prepare 1 x TE. 
 Isopropyl β-D-1-thiogalactopyranoside [1M] 
IPTG (Sigma,# I6758-1G)-4.7g 
H2O-20ml 
SDS [20%] 
SDS: 20g; dissolved in 100 ml water. 
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Ammonium Per Sulphate [20%] 
APS- 20g 
H2O- 100ml 
Resolving gel buffer:  
1.5 M Tris-HCl, pH 8.8 
Tris (Sigma) 12.1g 
HCl   3-4ml 
Makeup vol to 100ml 
Stacking gel buffer:  
0.5 M Tris-HCl (for stacking gel), pH 6.5 
Tris(sigma) 12.1g 
HCl 6-7ml 
Makeup vol to 100ml 
30% Acrylamide: 
Acrylamide:   29 %  
bis-Acrylamide: 1 % 
10X SDS-PAGE gel running buffer: 
 Tris base 30.3 g 
Glycine 144 g 
 SDS 10 g 
 H2O 1000 ml 
3X SDS-PAGE loading dye: 
1M Tris-HCl, pH 6.5  - 2.4 ml 
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20% SDS -3 ml 
Glycerol (100%) -3 ml 
B-mercaptoethanol -1.6 ml 
Bromophenol blue -0.006g 
H2O -10 ml 
SDS-PAGE staining solution: 
Coomassie blue R250- 0.4 % w/v 
Methanol- 30 % v/v 
Acetic acid 10 %v/v 
SDS-PAGE destaining solution: 
Methanol- 30 % v/v 
Acetic acid 10 %v/v 
Total Protein extraction buffer: 
50 mM Tris (pH 8.8) 
250 mM NaCl 
0.05% Triton-X 
UCHL1 10X  Assay Buffer: 
Tris-HCl (pH-8.0) -200mM 
EDTA- 5mM  
DTT   - 50Mm 
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Glycerol- 40-50% 
Bacterial strains: DH5 was the recipient strain for the plasmids used in 
cloning. BL21(DE3) pLysS was the strain used for recombinant protein 
expression. 
General Methods 
Preparation of competent E. coli cells by calcium chloride method: Competent E. 
coli cells of DH5α and BL21 (DE3) pLysS, were prepared as described by 
Alexander [1] using MnCl2 and CaCl2. A single colony of E.coli strain was 
inoculated in 25 ml of sterile 2x LB medium (in 250ml Erlenmeyer flask) and 
incubated in shaker at 200rpm/30C overnight. 1 ml of this preinoculum was 
added to sterile 200 ml 2x LB medium and grown in incubator shaker at 
30C/200rpm/4 hrs. The culture was then chilled for 1hr at 4C and cells were 
harvested by centrifugation at 4000 rpm for 15 min at 4C. The supernatant 
was discarded and the cell pellet was resuspended in 12 ml of acid salt buffer-A 
(ASB-A, Na.acetate-40 mM, CaCl2-100 mM, MnCl2-70 mM, pH 5.5) and incubated 
on ice for 1 hr. The ASB treated cells were then pelleted by centrifugation 
carried out at 3500 rpm for 15 min at 4C and resuspended in 4ml of ASB-B 
(Na.acetate-40 mM, CaCl2-100 mM, MnCl2-70 mM, 15% glycerol, pH 5.5) and 
were stored (aliquots of 100 l) at -86 C for future use. 
 Transformation of competent E. coli cells: DH5 or BL21 (DE3) pLysS 
competent E.coli cells were prepared as before. 10 ng of pure plasmid DNA or 5 
μl of a ligation mix were added to 50 μl aliquots of cells and the mixture was 
incubated on ice for 30 minutes. After a 42°C heat shock for 30 seconds, the 
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cells were briefly incubated on ice for 5 minutes before 200 μl of SOC media 
was added. This cell suspension was then incubated at 37°C for 1 hour, shaking 
at 250 rpm. After this incubation, 20 μl and 200 μl aliquots were plated on LB 
plates containing 100 μg/ml ampicillin and the plates were incubated at 37°C 
overnight. 
Quick transformation of BL21 (DE3) pLysS competent cells: BL21 (DE3) pLysS 
competent E.coli cells were prepared as before. 5 μl of a plasmid DNA was added to 
50 μl aliquots of cells and the mixture was incubated on ice for 5 minutes. After a 
42°C heat shock for 30 seconds, the cells were briefly incubated on ice for 5 
minutes. After this incubation, entire transformation mix was plated on LB plates 
containing 100 μg/ml ampicillin and the plates were incubated at 37°C overnight. 
Plasmid mini-prep: Mini-preps of plasmids were performed using the Plasmid 
Mini-Prep kits (Thermo Scientific #K0503) according to the instructions of the 
manufacturer. Standard culture volumes were 2 ml for minipreps. The purified 
plasmid DNA was analyzed by restriction digestion and agarose gel electrophoresis 
to confirm the identity of the obtained plasmid. Miniprep of plasmid DNA was also 
carried out by alkaline lysis method[32]. 
Restriction digests and ligation reactions: All restriction enzymes were purchased 
from New England Biolabs and used according to the manufacturer’s instructions. 
Ligation reactions were performed using T4-DNA ligase (New England Biolabs, cat 
#M0202S), used as recommended by the manufacturer. Whole ligation reactions 
were used for transformation into E. coli(DH5α). 
Agarose gel electrophoresis: Horizontal agarose gel electrophoresis unit (BIO-
RAD #166-4000EDU) was used for analysis of DNA. All agarose gels were 0.8% 
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w/v agarose (SeaKem LE, LONZA #50005)in 1xTAE (40mM Tris-acetate; 1mM 
EDTA pH 8.0). The samples were loaded in 1x loading dye (6x stock: 0.25% 
bromophenol blue; 0.25 xylene cyanol FF; 30% v/v glycerol). Gels also contained 
1μg/ml ethidium bromide to allow visualization of the DNA under UV light. The 
gels were viewed under Gel Documentation System (Syngene). Gels were run at 
100V. DNA ladder of 1 kb (Thermo Scientific, # SM0311) was used for fragment 
size determination. 
Purification of DNA from agarose gels (gel extraction): DNA was purified from 
agarose gels using GeneJET gel extraction kit from Fermentas Life Sciences cat 
#K0692, as instructed by the manufacturer. 
SDS-PAGE: Expression of recombinant protein was checked in 12.5% SDS-PAGE 
according to the standard protocol. SDS-PAGE was carried using discontinuous 
buffer system as described by Laemmli using slab gel electrophoresis apparatus 
[17].  Throughout this study 1.5 mm thick 12% polyacrylamide (30:0.8, acrylamide 
to bisacrylamide ratio) gel containing 0.1% SDS was used for electrophoretic 
separation of proteins. The protein samples were mixed with an equal volume of 3X 
loading dye(2.4 ml 1M Tris-HCl pH 6.5, 3 ml 20% SDS, 3 ml 100% Glycerol, 1.6 
ml β-mercaptoethanol, 0.006 g Bromophenol blue) and heated at 100 °C for 10 min 
and were loaded into the wells of precast polyacrylamide gel.  Electrophoresis was 
performed at a constant voltage of 100 or 120V using 0.025M Tris and 0.2 M 
glycine buffer pH 8.8 containing 0.1% SDS.  After the electrophoresis, the gel was 
stained with coommasie brilliant blue (0.4% w/v Coomassie blue R250, 30% v/v 
Methanol, 10 % Acetic acid) 
Checking the expression of the recombinant clones: E.coli BL21(DE3) cells 
transformed with recombinant plasmids were grown and induced for protein 
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expression as described by Studier et al [33, 34]. A single colony was inoculated in 
6 ml of Luria-Bertani medium containing 100g/ml ampicillin and grown for 4 hrs 
at 37
o
C in a screw-cap inoculation vial. From this culture 2ml culture was recovered 
as a reference for uninduced E.coli extract and the remaining 4ml culture was 
induced with 0.1mM (final concentration) isopropyl--D-thiogalactopyranoside 
(IPTG). Following induction the culture was further grown for 4 h at 37
o
C and 1.5ml 
culture was recovered from the induced sample as a reference for induced E.coli 
extract and 750 μl was recovered from uninduced culture. The induced and 
uninduced cells were harvested and resuspended in 100l protein extraction buffer 
(50 mM Tris pH 8.8, 250 mM NaCl, 0.05% Triton-X) and lysed by sonication. From 
the sonicated samples, 60l were added to 30l of 3x sample loading dye [17], 
boiled for 10 min and were used for SDS-PAGE analysis in 12% gel. The 
electrophoresis was carried out at 100 volts and the proteins were stained with 
Commassie brilliant blue. 
Cloning of human UCHL1 
Polymerase Chain Reaction (PCR) for UCH-L1 gene amplification: PCR master mix 
was prepared by adding water, buffer, dNTPs, primers and Taq DNA polymerase 
and template DNA (10 μl).  
 10 μl of 5 x Phusion High Fidelity Buffer 
 1 μl of dNTPs (10 mM each) 
 1μl of  primer-UCHL1-BamHI-Sen and UCHL1-SalI-HindIII-Anti (100 μM) 
 1 μl of Phusion High Fidelity DNA Polymerase 
 1μl of template DNA(pEGFP1-hUCHL1) 
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PCR grade water was used to reach the final reaction volume 50μl.  PCR 
temperature program for UCHL1 gene ampflication: 
1. 98
o
C, 30 sec 2. 98
o
C, 10 sec 3. 57
o
C, 30 sec 4. 72
o
C, 1 min  
5. 72
o
C, 10Min 6. 4
o
C, Hold; Step 2-4 were repeated for 32 cycles 
Ligation and screening: Full length UCH-L1 was PCR amplified in 50 μl reaction 
volume by using Phusion high fidelity DNA polymerase (New England Biolabs,# 
M0503S), 1 μl of pEGFP.C3.hUCHL1 as template and specific primers (UCHL1-
BamHI-Sen and UCHL1-SalI-HindIII-Anti). The amplification was examined by 
0.8% agarose gel electrophoresis using 1μg/ml ethidium bromide to allow 
visualization of the DNA under UV light. DNA ladder of 1kb (Thermo Scientific, # 
SM0311) was used for fragment size determination. The full length UCHL1 product 
and plasmid pRSETA were sequentially digested by BamHI and HindIII at 37
o
C/4h, 
in 40μl reaction volume containing each 1μl of restriction enzyme. The entire 
digestion mixture was loaded in 0.8% agarose gel. After electrophoresis the 
appropriate size bands were visualized on low intensity UV (340nm) light of UV 
trans-illuminator and excised using a sterile scalpel. DNA was eluted from the 
agarose gel piece according GeneJET kit protocol (Fermentas Life Sciences, cat 
#K0692). Ligation was set-up in 10 μl reaction with 7.5 μl of restriction digested 
and gel eluted PCR DNA(11.65 ng/µl), 0.5 μl of restriction digested and gel eluted 
vector(28.45 ng/µl),1µl of ligation buffer containing ATP and 1 μl of T4-DNA 
ligase (New England Biolabs, cat #M0202S) and incubated at 16
o
C/overnight. The 
entire ligation mixture was transformed to 50 μl of DH5α competent cells and grown 
on LB-plates containing 100 μg/ml ampicillin. After overnight incubation at 37oC, 9 
colonies were selected and grown in 2ml LB-ampicillin. Further, plasmid was 
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purified by alkaline lysis method [38]. To confirm the presence of UCH-L1 and also 
orientation , restriction analysis of the slow moving clones was performed using 
enzymes NcoI and ScaI.  
 
Table 1  
Purpose Name Sequence (5’ – 3’) 
Forward primer for cloning 
UCHL1 
UCHL1-BamHI-Sen 
(40nt) 
CCTGGGATCCATGCAGCTCAAGCCG
ATGGAGATCAACCCC  
Reverse primer for cloning 
UCHL1 
UCHL1-SalI-HindIII-
Anti (43nt) 
AAAAGTCGACAAGCTTTTAGGCTGC
CTTGCAGAGAGCCACGGC  
Forward primer for cloning 
Ubiquitin 
Ub-NdeI-Sen 
(38nt) 
GATATACATATGCAGATCTTCGTGA
AGACTCTGACTGG 
Reverse primer for cloning 
Ubiquitin 
Ub-HindIII-Anti 
(56nt) 
GCCTAGAAGCTTCTAGCAATGATGA
TGATGATGATGCTTCCCACCTCTGA
GACGGAGTACC 
Forward primer for Ub-
K63C 
Ub-K63C-Sen  
(52nt) 
CCCTGTCTGACTACAACATCCAGTG
TGAGTCCACCTTGCACCTGGTACTC
CG 
Reverse primer for Ub-
K63C 
Ub-K63C-Anti  
(52nt)        
CGGAGTACCAGGTGCAAGGTGGACT
CACACTGGATGTTGTAGTCAGACAG
GG 
 
Purification of UCH-L1 
The recombinant soluble protein was purified by Ni-NTA affinity 
chromatography. For this, few BL21+pRSETA-UCHL1 transformed colonies 
were inoculated into 100ml LB-broth with 100 μg/ml ampicillin and grown on 
incubatory shaker at 37oC at 200 rpm. The grown culture was 20 fold diluted 
into 2L fresh TB-broth with 100 μg/ml ampicillin. Incubation was carried out at 
37oC at 200 rpm for 3 hrs. The culture was then induced with 1mM IPTG and 
kept for 5 hrs at 30oC at 200 rpm. Cells were harvested after centrifugation at 
8000 rpm for 15 minutes at 4oC. The cell pellet was resuspended in 20ml of 
50mM Tris-HCl buffer (pH 8.0) containing 300mM sodium chloride, 0.1% 
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Triton-X, 1mM Imidazole and sonicated for 30 minutes. The sample was then 
centrifuged at 14,000 rpm for 20 minutes at 4oC to remove insoluble debris. 
The soluble fraction was mixed with 2ml of Ni-NTA resin pre-equilibrated with 
the same buffer and allowed to rotate in rotary shaker for 4h to allow the 
protein to bind to the resin. The sample was then centrifuged at 1000 g for 5 
minutes at 4oC and the washing is carried out in 3 steps with 75 ml wash buffer 
(50 mM Tris,pH8.0, 350 mM NaCl, 0.1% Triton-X and 5 mM Imidazole). 
Centrifugation was carried out at 1000g for 4 minutes at 4oC. Bound protein 
was eluted with elution buffer (10 mM Tris,pH8.0, 100 mM NaCl, 400 mM 
Imidazole). 1.5ml of elute1, 1ml of elute 2 and 1ml of elute 3 was collected. All 
elutes were checked in 12% SDS-PAGE. 
Cloning of Ubiquitin with C-terminal extension (Ub) 
Deubiquitinase activity of UCHL1 was checked in vitro by using the Ub having a C-
terminal extension peptide (Lys-His-His-His-His-His-His-Cys). UCHL1 is reported 
to cleave the bond present between C-terminal glycine of Ubiqitin and a short 
peptide, preferably starting with lysine. Therefore, the peptide substrate was 
designed with lysine after the last amino acid of Ub (Glycine) followed by six 
histidine and a cysteine. This Ub C-terminal extension peptide would help in Ni-
NTA purification of ubiquitin, detection using anti-His tag antibody and analysis of 
endopeptidase activity of UCHL1.   
Polymerase Chain Reaction (PCR) for Ub gene amplification: PCR reaction of 25µl 
for ampflication of Ub contained 
 5 μl of 5 x Phusion High Fidelity Buffer 
 0.5 μl of dNTPs (10 mM each) 
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 0.25μl of primer-Ub-NdeI-Sen and Ub-HindIII-Anti  (100 μM)  
  0.5 μl of Phusion High Fidelity DNA Polymerase 
 0.5μl of template DNA(pGEX-Ubiquitin) 
PCR grade water was used to reach the final reaction volume 25μl. PCR temperature 
program for Ubiquitin gene amplification: 
1. 98
o
C, 30 sec 2. 98
o
C, 10 sec    3. 56
o
C, 30 sec 4. 72
o
C, 1 min 30 sec;  
5. 72
o
C, 10Min 6. 4
o
C, Hold; Step 2-4 were repeated for 32 cycles 
Ligation and screening: Full length Ubiquitin was PCR amplified in 50 μl reaction 
volume by using Phusion high fidelity DNA polymerase (New England Biolabs, 
#M0503S), 1 μl of pGEX- Ubq as template and primers Ub-NdeI-Sen and Ub-
HindIII-Anti. The amplification was examined by 0.8% agarose gel electrophoresis 
using 1μg/ml ethidium bromide to allow visualization of the DNA under UV light. 
DNA ladder of 1kb (Thermo Scientific, # SM0311) was used for fragment size 
determination. The full length Ubiquitin product and plasmid pRSETA were 
sequentially digested by NdeI and HindIII at 37
oC/4h, in 40μl reaction volume 
containing each 0.5μl of restriction enzyme. The entire digestion mixture was loaded 
in 0.8% agarose gel. After electrophoresis the appropriate size bands were visualized 
on low intensity UV (340nm) light of UV trans-illuminator and excised using a 
sterile scalpel. DNA was eluted from the agarose gel piece according GeneJET kit 
protocol (Fermentas Life Sciences, cat  #K0692). Ligation was set-up in 10 μl 
reaction with 6.5 μl restriction digested and gel eluted PCR DNA (8.3ng/µl),1μl 
ligation buffer, 1.5 μl  restriction digested  and gel eluted vector( 23.95ng/µl) and 1 
μl of T4-DNA ligase containing ATP (New England Biolabs,cat #M0202S) and 
incubated at 16
oC/overnight. The entire ligation mixture was transformed to 50 μl of 
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DH5α competent cells and grown on LB-plates containing 100 μg/ml ampicillin. 
After overnight incubation at 37
o
C, 9 colonies were selected and grown in 2ml LB-
ampicillin. Further, plasmid was purified by alkaline lysis method [32]. To confirm 
the presence of Ubiquitin in right orientation, restriction analysis of the slow moving 
clone was performed using enzymes NdeI and HindIII.  
Site directed mutagenesis of Ub at position Lys63 to Cys63 to 
generate ubiquitin containing two-thiol  groups (Ub-SH) 
 
The entire plasmid-containing mutant Ubiquitin was amplified by the two 
overlapping oligonucleotides that carried the specific mutation. A reaction of 50μl 
contained for mutation PCR contained: 
 10 μl of 5 x Phusion High Fidelity Buffer 
 1 μl of dNTPs (10 mM each) 
 0.25μl of each primer- Ub-K63C-Sen and Ub-K63C-Anti100µM 
 1 μl of Phusion Q5 hot start DNA Polymerase 
 1μl of template DNA(pRSETA-Ubiquitin) 
PCR grade water was used to reach the final reaction volume 50μl. PCR temperature 
program for mutagenesis: 
1. 98
o
C, 30 sec 2. 98
o
C, 10 sec 3. 56
o
C, 30 sec 4. 72
o
C, 1 min 
30 sec;  5. 72
o
C, 10Min 6. 4
o
C, Hold; Step 2-4 were repeated for 20 cycles 
To remove the non-mutated template plasmid, the entire PCR mixture was treated 
with 1μl of DpnI digestion at 37oC for overnight incubation, which degrades 
specifically methylated DNA that is template plasmid purified from bacterial host. 
DpnI digested PCR mixture was then transformed to 50μl DH5α competent cells 
and grown on LB agar plates containing 100μg/ml ampicillin. After overnight 
incubation the colonies were inoculated to 2ml of LB-ampicillin and plasmid was 
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purified from grown culture using plasmid purification kit (Fermentas Life Sciences) 
according to manufacturer’s instructions 
Purification of Ub and Ub-SH 
Purification of Ub: Purification was carried out in one step by affinity 
purification using Ni-NTA chromatography. Few BL21+pRSETA-Ub 
transformed colonies were inoculated into 100 ml LB-broth with 100 μg/ml 
ampicillin and grown on incubatory shaker at 37oC at 200 rpm. The grown 
culture was 20-fold diluted into fresh 2L TB-broth with 100 μg/ml ampicillin. 
Incubation was carried out at 37oC at 200 rpm for 3 hrs. The culture was then 
induced with 1mM IPTG for 5 hrs at 30oC at 200 rpm. Cells were harvested after 
centrifugation at 8000 rpm for 15 minutes at 4oC. The cell pellet was 
resuspended in 50ml of extraction buffer (50mM Tris-HCl buffer (pH 8.0) 
,300mM sodium chloride, 0.1% Triton-X, 1mM Imidazole) and sonicated for 40 
minutes. The sample was then centrifuged at 14,000 rpm for 20 minutes at 4oC 
to remove insoluble debris. The soluble fraction was then heated for 10 min at 
70 oC and again centrifuged at 14000rpm/20min/4oC. After this the soluble 
fraction was mixed with 2ml of Ni-NTA resin pre-equilibrated with the same 
buffer and allowed to rotate in rotary shaker for 4h to allow the protein to bind 
to the resin. The sample was then centrifuged at 1000 g for 5 minutes at 4oC 
and flow through was collected. Washing was then carried out in 3 steps with 
75 ml wash buffer (50 mM Tris,pH8.0, 350 mM NaCl, 0.1% Triton-X and 5 mM 
Imidazole) with 10 min washing on rotor. Centrifugation was carried out at 
1000g for 4 minutes at 4oC. Bound protein was eluted with 8ml elution buffer 
(10 mM Tris,pH8.0, 100 mM NaCl, 250 mM Imidazole). 1.5ml of elute 1,1 ml of 
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elute 2 and 1 ml of elute 3 was collected. All elutes were checked in 15% SDS-
PAGE. 
Purification of Ub-SH: The mutant protein containing two thiol groups was 
purified exactly like Ub described before. 
 
Qualitative analysis of enzymatic hydrolysis of Ub-SH 
The in vitro assay of UCHL1 activity on Ub substrate was performed by using 48g 
(15.0M) of UCHL1 and 50g (100M) of Ubiquitin in a 50l reaction in 10X 
assay buffer. Reaction mix was incubated 2h at 30°C for the activity of UCHL1 to 
occur. Identical reaction was also carried out with catalytic mutant of C90A 
UCHL1. Activity of wild type UCHL1 and the mutant UCHL1 on the Ub C-terminal 
extension peptide was analyzed by Gradient SDS PAGE gel (4-15%) from 
BIORAD. 
Preparation of gold nanoparticles 
The synthesis is based on the reduction of gold chloride by sodium citrate at specific 
concentrations and at a temperature high enough for the sodium citrate to act as a 
reducing agent (around 80-100°C), and thus causing the gold to be reduced from 
Au(III) to Au(0). Citrate serves a dual purpose in the synthesis; it serves to both 
reduce the gold and stabilize the particles. In the zero oxidation state, gold atoms 
start to nucleate and grow into particles. Usually a stabilizing agent is also added to 
prevent the particles from aggregating. Because thiol groups bind to gold surfaces 
with high affinity, most frequently thiol modified ligands are used as stabilizing 
agents which bind to the surface of the AuNPs by formation of Au-sulfur bonds. 
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Synthesis of AuNPs with various sizes and shapes can be achieved through judicious 
choice of experimental conditions and reagents. 
Reagents required for synthesis of gold nano-particles of different sizes were: 
(A) 0.25 mM HAuCl4 (4.9mg HAuCl4 (MW 393.83) dissolved in 50ml deionised 
water). (B) 1% Sodium citrate (0.2g Sodium citrate was added to 20 ml 
deionized water). 50ml aqueous solution of HAuCl4 (0.25 mM) was heated to 
boiling on a stir/hot plate while stirring with the magnetic stir bar. After the 
solution started to boil, 1.6ml, 0.875ml, 0.625ml, 0.5ml of trisodium citrate 
(1%) was added to get 10nm, 20nm, 32nm and 41nm AuNP respectively (Table 
2). In about 25 s, the boiling solution turned faintly blue (nucleation). After 
approximately 70 s, the blue color suddenly changed into a brilliant red, 
indicating the formation of gold particles. The solution was continued to boil 
and stirred until deep red color (about 10 min) was obtained. While the 
solution was boiling, a few drops of distilled water was added to keep the total 
solution volume near 50 mL. The particles formed by this method was allowed 
to stand for 24h before their use for further studies. Gold nanoparticle solution 
is stable for months if stored in covered glass containers at room temperature. 
All concentration determinations were done with UV-Vis measurements.  
Table 2. 
Volume 
of 
HAuCl4  
HAuCl4   
(mM) 
Vol of 
1% 
sodium 
citrate  
Sodiu
m 
citrate 
(mM) 
Λ max Average diameter 
(nm) 
Reporte
d 
Observed Reported Observed 
50ml 0.25 1.6    ml 1.09 519 522.50 10 10 
50ml 0.25 0.875ml 0.59 526 528.50 20 20 
50ml 0.25 0.625ml 0.43 529 528.00 32 32 
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50ml 0.25 0.500ml 0.34 532 532.50 41 41 
 
Characterization of gold nanoparticles 
Electron microscopy: A 2 μL drop of nanoparticle solution at a concentration of 0.1 
mg/mL in milliQ H2O was dried onto a carbon coated grid and viewed under a Leo 
912 AB TEM at 120kV, at 40,000× magnification. 
Aggregation of gold nanoparticles by ubiquitin containing two-
thiol groups detected by Surface plasmon resonance  
 
A strong broad absorption band is observed in the absorption spectra of many 
metallic nanoparticles, especially gold and silver. This occurs because of the 
coupling of incident electromagnetic radiation into a surface Plasmon, 
(described as a collective oscillation of the conduction electrons) at the 
interface between the particle and the medium surrounding the particle. The 
resulting energy loss is manifested as an absorbance known as surface Plasmon 
band. Being confined to the surface, this collective oscillation of the free 
electrons is sensitive to changes in the size of particle and as the diameter gets 
smaller the energy required to collectively excite motion of the surface Plasmon 
electrons increases. Gold nanoparticles with diameters greater than 5nm have 
maxima at longer wavelengths and by varying the particle size one can tune the 
maximum of the SPR absorbance to be anywhere from 520nm to 1000nm. Any 
species adsorbed to the nanoparticle surface will manifest a colour change 
(shift in SPR peak position) proportional to magnitude of the change in 
refractive index near the nanoparticle surface(40). We carried out surface 
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modification of 30nm gold nanoparticles with purified Ub-SH peptide. To 
achieve this, the reaction mix was prepared as follows:  
Table 3. 
Chemical  Reaction Vol  Concentration 
AuNP  200  μl  50.0μM  
Ub-SH 15 μl  0.25μM  
Water  785 μl  -  
Total =  1000 μl  -  
 
Ubiquitin containing two thiol groups substrate was taken along with the amount of 
water required for the reaction, which was then tapped and given a brief spin to 
ensure proper mixing. After this AuNP was added to the reaction mix. The total 
reaction mix was then transferred to polystyrene cuvettes and the reaction was 
allowed to run for 30 min with a time interval of 5min. The resulting UV/Vis 
absorption spectra were obtained using U-3900 spectrophotometer (Hitachi). 
Similarly, experiments were carried out with ubiquitin lacking two terminal 
cysteines as negative control. In this the reaction mix was prepared as follows:  
 
Table 4. 
Chemical  Reaction Volume Concentration 
AuNP  200  μl  50.0μM  
Ubiquitin  15 μl  0.25μM  
Water  785 μl  -  
Total =  1000 μl  -  
 
 
Dispersion of Gold Nanoparticles by UCHL1 and detection by 
surface plasmon resonance 
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To induce dispersion of aggregated gold nanoparticles due to two-thiol substrate, 
different amounts of recombinant UCH-L1 was added to the 30nm gold 
nanoparticles and spectral changes were recorded. The reaction mix was prepared as 
described in Table 5. 
Table 5. 
Chemical Reaction Volume  Concentration 
AuNP 200  μl  50.0μM  
HS-Ubi-SH 15 μl  0.25μM  
UCHL1 5 μl  1.25µM 
H2O 780 μl   
Total= 1000μl   
 
UCHL1 was diluted following the scheme as mentioned in Table 6. The reaction 
was then kept for 2h incubation at 37C and the required reaction volume was made 
to 1 ml with water. After this AuNP was added to the reaction mix. The total 
reaction mix (1ml) was then transferred to polystyrene cuvettes and the reaction was 
allowed to run for 30 min with a time interval of 5min. The resulting UV/Vis 
absorption spectra were recorded in U3900 spectrophotometer (Hitachi) and the 
observed change in wavelengths was noted. 
 
Table 6. 
 
 
 
 
 
 
 
Stock 
Dilution 
Final concentration 
in cuvette (ng/ml) 
  
1:10 180 
  
1:20  90 
   
1:40 45 
  
1:100 18 
  
1:1000 1.8 
  
1:10000 1.8 
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Fluorescence-based UCHL-1 assay using Ubiquitin-AMC 
UbAMC was dissolved water to make stock solution of final concentration of 100 
M.  Different dilution of UCH-L1 was made as mentioned in the Table 7 and 
UbAMC (5M) were mixed in reaction buffer (10 mM Tris•HCl, pH 8.0) was added 
to initiate the enzymatic reaction (300 μL final volume).  The rate of AMC cleavage 
was monitored at 25°C with a Molecular Devices spectrofluorometer with excitation 
at 340 nm and emission at 440 nm.  
 
Table 7. 
Chemical Reaction Volume  Concentration 
Ub-AMC 15  μl  5 μM  
100mM Tris-HCl, pH 8.0 30 μl  10 mM  
UCHL1 30 μl  see Table 8 
H2O 225 μl   
Total= 300 μl   
 
 
Table 8. 
Stock UCHL1  
conc. (ng/ml) 
Dilution 
Factor 
Dilution 1 Conc. in  
Dil. 1 
Dilution 2 Concentration 
in cuvette (ng/ml) 
A      
10
7
 1:1000 10l UCHL1  
+ 990l H2O 
10
5
 30l of Dil-1  
in 300l H2O 
10
4
 
B      
10
7
 1:10000  100l of A  
+ 900l H2O 
10
4
 30l of Dil-1  
in 300l H2O 
10
3
 
C       
10
6
 1:100000 100l of B  
+ 900l H2O 
10
3
 30l of Dil-1  
in 300l H2O 
10
2
 
D      
10
6
 1:200000 50l of B  
+ 500l H2O 
500 30l of Dil-1  
in 300l H2O 
50 
E      
10
6
 1:400000 25l of B  
+ 500l H2O 
250 30l of Dil-1  
in 300l H2O 
25 
F      
10
6
 1:1000000 100l of C 
+ 900l H2O 
10
2
 30l of Dil-1  
in 300l H2O 
10 
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Chapter 3 
 
Results and Discussion 
 
4.1 Cloning, Expression and purification of UCH-L1: Full length UCH-L1 was 
PCR amplified and examined by 0.8% agarose gel electrophoresis. The expected 
PCR amplification of size 672 bp was obtained. The full length UCHL1 product and 
plasmid pRSETA were sequentially digested by BamHI and HindIII and ligated.  
The clone was selected by slower mobility compared to negative control (pRSETA). 
To confirm the presence of UCH-L1 and also orientation, restriction analysis of the 
slow moving clones was performed using enzymes NcoI and ScaI. The insert release 
of 1200 bp confirms the presence of UCH-L1 gene in correct orientation (Fig. 1).   
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For recombinant protein expression, Escherichia coli BL21(DE3) cells were 
transformed with pRSETA-UCHL1. These cells were grown and induced for protein 
expression by IPTG. Expression of the recombinant protein was confirmed by SDS-
PAGE analysis in 12% gel and staining with coomassie brilliant blue (Fig. 2). Since 
the proteins had the C-terminal his tag, they were purified by Ni-NTA affinity 
chromatography (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
4.2 Designing of UCH-L1 substrate. We designed the peptide substrate with two 
salient features: (a) Two thiol-groups at the two termini of the molecule (To 
facilitate aggregation of gold NPs) (b) An additional lysine residue to the carboxy-
terminal of 76 amino-acid ubiquitin (as UCHL1 cleaves the peptide bond between 
the carboxy-terminal glycine residue (Gly
76
) of ubiquitin and the subsequent lysine 
residue (Lys
77
)) [19]. In order to create the UCHL1 substrate containing two 
terminal thiol groups (Ub-SH), a cysteine residue (Cys
84
) was added as the last 
residue of the substrate at the carboxyl-terminus. In order to create the other terminal 
thiol-groups on ubiquitin molecule, lysine at position 63 (Lys
63
) was decided be 
3 
mutated to cystine by site-directed mutagenesis, as structure of ubiquitin clearly 
reveals that Lys
63
 is located complete opposite to carboxy-terminus of ubiquitin. 
Thus the substrate peptide will have two cysteine thiol groups (from Cys
84
 and 
Cys
63
) at the head and tail position of the molecule. The C-terminal eight amino 
acids (containing the Lys
77
, 6x His and Cys
83
) were added to ubiquitin sequence 
during cloning using a specific PCR primer (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
4.3. Cloning of Ub with C-terminal extension with single thiol group: Full length 
Ubiquitin was PCR amplified and examined by 0.8% agarose gel electrophoresis. 
The expected PCR amplification of size 255 bp was observed. The full length 
Ubiquitin product and plasmid pRSETA were sequentially digested by NdeI and 
HindIII and ligated. The entire ligation mixture was transformed to 50 μl of DH5α 
competent cells and grown on LB-plates containing 100 μg/ml ampicillin. After 
overnight incubation at 37
o
C, 9 colonies were selected and grown in 2ml LB-
ampicillin. Further, plasmid was purified by alkaline lysis method [32]. Of the 9 
colonies analyzed, 1was moving slow compared to negative control (pRSETA). To 
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confirm the presence of Ubiquitin in right orientation, restriction analysis of the 
slow moving clone was performed using enzymes NdeI and HindIII. The insert 
release of 255 bp confirms the presence of Ubiquitin gene in correct orientation. For 
recombinant expression of Ub, Escherichia coli BL21(DE3)pLysS cells transformed 
with pRSETA-Ub. These cells were grown and induced for protein expression by 
1mM IPTG. Expression of the recombinant protein was confirmed by SDS-PAGE 
analysis in 12% gel and staining with coomassie brilliant blue. The size of the 
recombinant Ub substrate was 9.63 kDa. Among the clones analyzed 1 clone was 
positive for overexpression of Ubiquitin (Fig. 5).  
 
 
 
 
 
 
 
 
 
 
 
 
4.5 Site-directed mutagenesis to generate Ub-SH: Using specific 
oligonucleotides, Lys63 of Ub was mutated to Cys63. The mutation was confirmed 
by sequencing (Fig. 6). 
  
5 
4.6. Expression and purification of Ub-SH: Recombinant Ub-SH containing 
Cys63 mutation and C-terminal 6-his tag was expressed in Escherichia coli 
BL21(DE3)pLysS cells and induced for protein expression by 1mM IPTG. 
Expression of the recombinant protein was confirmed by SDS-PAGE analysis in 
12% gel and staining with coomassie brilliant blue. Expressed protein was then 
purified by Ni-NTA affinity purification (Fig. 7).  
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4.9 The synthesis of citrate stabilized gold nanoparticles: The gold nanoparticles 
(AuNPs) used in this work were synthesized by the reduction of HAuCl4 with 
citrate. Similar procedures for gold nanoparticles synthesis has been demonstrated 
before. Protocols also enabled the preparation of approximately 20-40 nm spherical 
particles with narrow size distribution were used. Among different nanoparticles, 
30nm particles were characterized using TEM, DLS and UV-Vis spectroscopy (Fig. 
8).  
 
 
 
 
 
 
 
 
 
 
4.10 Characterization of 30nm gold nanoparticles:  The synthesized AuNPs were 
characterized by transmission electron microscopy (TEM) and UV-Vis absorption 
spectroscopy. The photograph seen in Fig. 8 is from a sample of 30nm particles 
synthesized according to the procedure described in previous section. Fig. 8 shows 
the TEM image of the particle; spherically shaped nanoparticles and a few triangular 
or ellipsoidal shaped particles could be seen. The diameter of the nanoparticles is 
~30.0 nm and the plasmon absorption peak is at 529 nm. Characteristically, gold 
nanoparticles show surface plasmon absorption in the UV-visible absorption 
7 
spectrum. The absorption peak positions are dependent on the medium surrounding 
of the particles. A change in the nature of constituent surrounding ligand shell 
results to shift of the peak. Characterization of the prepared citrate stabilized AuNPs 
was done by determination of their extinction coefficients as well as observing their 
absorption peaks and absorption curve appearances. Figure 9 shows the resulting 
absorption spectra of the analyzed AuNP samples, each having absorption maximum 
falling within the spectral range of 520 nm to 535 nm wavelength. Their maximum 
absorption peaks, Amax values are summarized in table 2. According to the 
observation made in Fig. 9, the maximum peak shifts to longer wavelength (red-
shift) with increasing particle size.  
 
 
 
 
 
 
 
 
 
4.9 Aggregation of gold nanoparticles using two-thiol Ub substrate: Aggregation 
of 30nm gold nanoparticles (0.25 mM HAuCl4, 1% trisodium citrate) was induced 
by  purified two-thiol Ub substrate. To induce aggregation 15l of peptide 
(2.40µg/ml;0.25 µM) was added to 30nm gold nanoparticles (200µl; 50µM). The 
aggregation of coated gold nanoparticles took 30 min to complete. However, a color 
change from red to purple was observed within 1-2 min. To maximize the absorption 
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change at 650 nm, we used an assay time of 30 min. At longer times, precipitation of 
large aggregates and a clear supernatant are observed and absorption intensity is no 
longer concentration-dependent. The UV/vis absorption spectra of solution 
containing coated gold nanoparticles is shown in Figure 9.  
 
 
 
 
 
 
 
 
 
 
 
5.0 Aggregation of Gold nanoparticle is specific. To confirm that the aggregation 
that we are observing is specific to gold nanoparticle, we added (15µl, 
2.40µg/ml/0.25µM) ubiquitin substrate with single thiol group. As shown in figure 
Figure 10, no aggregation of gold nanoparticle was observed. Curve "a" shows the 
absorption spectrum at 650 nm of a solution containing Ub (single thiol groups). 
Curve "b" shows the absorption profile at 650 nm of a solution containing Ub-SH 
(two thiol groups). When we analyzed the time course of absorption change after 
adding Ub and Ub-SH peptide, we noticed that absorption intensity at 650 nm 
remained constant as seen from the graph at time 0 min and 30 min with Ub, 
indicating that aggregation did not take place. This is attributed to the lack of 
9 
multiple binding sites and the inability to form non-specific aggregates among a 
large numbers of particles. To test the specificity we also used Ub-SH which is 
cleaved by UCHL1. As shown in figure 11(a), when the peptide was added to the 
gold colloids, gradual change of the absorbance was obvious (Fig. 11).  
Ub-SH 
 
 
Ub 
 
 
 
                             a 
 
                                                         b 
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4.11. The dispersal of gold nanoparticles using recombinant UCH-L1. To induce 
dispersion of aggregated gold nanoparticles due to two-thiol substrate, recombinant 
UCH-L1 was added to the nanoparticle solutions and spectral changes were 
recorded as shown in Figure 12. Interestingly, the color changes were obtained in 
the presence of 5μl UCH-L1 (1.25μM/38μg/ml) range only. The spectral and 
colorimetric changes were obtained immediately when higher concentration of 
11 
UCH-L1 was added to the gold nanoparticle solution, due cleavage of the peptide 
substrate. 
 
 
 
 
 
 
 
 
 
 
4.12. Sensitivity of AuNP-based assay using thiol containing UCHL1 substrate 
and recombinant UCHL1. To increase the sensitivity of AunP-based assay using 
thiol containing substrate and recombinant UCHL1, the concentration of the gold 
nanoparticles was increased from 0.25mM to 0.50mM. Then, to induce dispersion of 
aggregated nanoparticles, recombinant UCHL1 was added to aggregated 
nanoparticle solution at various concentrations and the absorbance spectrum for each 
sample was scanned between 400 and 800 nm. The 650/530 nm ratio (A650/A530) 
was then plotted against UCHL1 concentration (Fig. 13). The concentration of 
UCHL1  used in these reactions (1.8-180 ng/ml UCHL1) were close to the amount 
of UCHL1 released in the blood serum following brain injury. To assess sensitivity 
of this gold nanoparticle based assay we also performed Ub-AMC based UCHL1 
assay.  Figure 14 shows UCHL1 catalysed hydrolysis of Ub-AMC at several 
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concentration of UCHL1.   UCHL1 catalysed hydrolysis of Ub-AMC releases AMC 
which showed emission at 440nm. When we plotted UCHL1 concentration against  
free AMC fluorescence, we detected similar UCHL1-dependen hydrolysis of Ub-
AMC (Fig 15). Therefore, novel gold nanoparticle based assay described here, can 
be used to detect functional UCHL1 in vitro via a hydrolysis of a short peptide 
containing ubiquitin with similar sensitivity in comparison with presently available 
fluorescence-based assay. 
 
 
 
 
 
 
 
 
 
 
The relevance of this nanoparticle-based assay includes that it does not require 
nanoparticle functionalization or any specific instrumentation; simple colorimetric 
analysis qualitative detection of UCHL1 that can be performed unlike fluorescence 
based assay where Ub-AMC has two critical disadvantages. First, AMC has an 
excitation wavelength in UV range, thus exciting at 240 -360nm is known to excite a 
significant number of screening compounds and thus will generate a large fraction of 
false positives. Second, AMC is covalently attached to C-terminal COOH of 
13 
ubiquitin and not via a e-NH2 group as found under physiological conditions (41).  
Therefore, the nanoparticle-based  assay could be used for the preliminary analysis 
of biological fluids without referring to specialized laboratories. Nevertheless, it 
provides a sensibility comparable to that provided by the Fluorescence-based assay.  
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